Home

Alan B. Sandler

CIK 1835966 · Chief Medical Officer · last filed 2026-01-21

Alan B. Sandler is a Chief Medical Officer who has filed 17 SEC Form 4 insider transactions across 4 companies since 2021. The most recent filing, for ALXO, was dated Jan 21, 2026. Current disclosed insider exposure totals $539.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$539.7K

Companies

4

Total Filings

17

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALXO Chief Medical Officer — $1.99 — $0 5 2026-01-21
Elevation Oncology, Inc. (ELEV) Delisted Director — $0.36 — $0 4 2025-07-24
Mirati Therapeutics, Inc. (MRTX) Delisted Chief Medical Officer 17,021 $58.70 $999.1K $0 4 2024-01-23
ZLAB Head of Global Dev., Oncology 28,985 $18.62 $539.7K $0 4 2022-06-27

Recent Filings

17 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-21 ALXO Grant (A) — $0 EDGAR
2025-07-24 Elevation Oncology, Inc. (ELEV) Delisted Disp (D) — $0 EDGAR
2025-06-09 Elevation Oncology, Inc. (ELEV) Delisted Grant (A) — $0 EDGAR
2025-04-15 ALXO Grant (A) — $0 EDGAR
2025-01-23 ALXO Grant (A) — $0 EDGAR
2024-11-19 ALXO Grant (A) — $0 EDGAR
2024-08-07 ALXO Grant (A) — $0 EDGAR
2024-06-17 Elevation Oncology, Inc. (ELEV) Delisted Grant (A) — $0 EDGAR
2024-03-04 Elevation Oncology, Inc. (ELEV) Delisted Grant (A) — $0 EDGAR
2024-01-23 Mirati Therapeutics, Inc. (MRTX) Delisted Disp (D) −79,865 $0 EDGAR
Showing 1–10 of 17
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.